Dietary potassium intake linked with blood potassium concentration in patients with CKD: study

Written By :  Dr. Shravani Dali
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-09-15 03:45 GMT   |   Update On 2022-09-15 08:13 GMT

Dietary potassium intake is linked with blood potassium concentration in patients with CKD according to a recent study published in the Journal of the American Society of Nephrology. Observational studies suggest that adequate dietary potassium intake (90–120 mmol/day) may be renoprotective, but the effects of increasing dietary potassium and the risk of hyperkalemia are...

Login or Register to read the full article

Dietary potassium intake is linked with blood potassium concentration in patients with CKD according to a recent study published in the Journal of the American Society of Nephrology.

Observational studies suggest that adequate dietary potassium intake (90–120 mmol/day) may be renoprotective, but the effects of increasing dietary potassium and the risk of hyperkalemia are unknown.

This is a prespecified analysis of the run-in phase of a clinical trial in which 191 patients (age 68±11 years, 74% males, 86% European ancestry, eGFR 31±9 ml/min per 1.73 m2, 83% renin-angiotensin system inhibitors, 38% diabetes) were treated with 40 mmol potassium chloride (KCl) per day for 2 weeks.

Results:

  • KCl supplementation significantly increased urinary potassium excretion, plasma potassium, and plasma aldosterone, but had no significant effect on urinary sodium excretion, plasma renin, BP, eGFR, or albuminuria.
  • Furthermore, KCl supplementation increased plasma chloride and reduced plasma bicarbonate and urine pH, but did not change urinary ammonium excretion.
  • In total, 21 participants (11%) developed hyperkalemia
  • They were older and had higher baseline plasma potassium.

The researchers concluded that in patients with CKD stage G3b–4, increasing dietary potassium intake to recommended levels with potassium chloride supplementation raises plasma potassium by 0.4 mmol/L. This may result in hyperkalemia in older patients or those with higher baseline plasma potassium. Longer-term studies should address whether cardiorenal protection outweighs the risk of hyperkalemia.

In the study Higher baseline plasma potassium and older age were risk factors for developing hyperkalemia after supplementation. Potassium chloride supplementation did not lower office BP, but did cause a tendency toward hyperchloremic metabolic acidosis. Longer-term studies should determine whether the cardiorenal benefits of adequate dietary potassium intake outweigh the risk of hyperkalemia in patients with CKD.

Reference:

Martin Gritter, et al. Effects of Short-Term Potassium Chloride Supplementation in Patients with CKD. JASN September 2022, 33 (9) 1779-1789; DOI: https://doi.org/10.1681/ASN.2022020147

Tags:    
Article Source : Journal of the American Society of Nephrology

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News